Galapagos extends drug discovery collaboration with Amgen into 2010

Mechelen, Belgium; 18 December 2008 – Galapagos NV (Euronext: GLPG) announced today that its service division BioFocus DPI has extended its longstanding drug discovery collaboration with Amgen through 2009 and 2010.  BioFocus DPI will continue to provide biology, computational and medicinal chemistry services and will supply small molecule compounds for use in Amgen’s discovery programs.  Under the terms of the extended agreement, Galapagos will receive €2.0 M ($2.55 M) in research fees per year for two years.  Additionally, Galapagos is eligible to receive compensation in the form of access fees and success-based milestones.
The collaboration, which was initiated in 2003 and extended in 2006, involves the identification of new molecules against drug targets from various protein classes, including ion channels, GPCRs and kinases.  
“We are pleased to extend our strong collaborative relationship with Amgen,” said Dr. Chris Newton, Senior VP BioFocus DPI.  “We are looking forward to applying our screening expertise and unique compound libraries to continue to provide lead candidates for Amgen’s discovery programs over the next two years.”
About Galapagos and BioFocus DPI
Galapagos (Euronext Brussels: GLPG; Euronext Amsterdam: GLPGA; OTC: GLPYY) is a drug discovery company with pre-clinical programs in bone and joint diseases and bone metastasis.  Its division BioFocus DPI offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.  BioFocus DPI also provides adenoviral reagents for rapid identification and validation of novel drug targets, compound libraries for drug screening as well as ADMET products to select compounds.  Galapagos currently employs 460 people and operates facilities in six countries, with global headquarters in Mechelen, Belgium.  More information about Galapagos and BioFocus DPI can be found at and
Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6290 98028
This release may contain forward-looking statements, including, without limitation, statements containing the words “believes,” “anticipates,” “expects,” “intends,” “plans,” “seeks,” “estimates,” “may,” “will,” “could,” “stands to,” and “continues,” as well as similar expressions.  Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements.  Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.  These forward-looking statements speak only as of the date of publication of this document.  Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.